Puerto Vallarta, Jalisco, Mexico – June 21, 2024—Ion Biotechnology México, S.A. de C.V. proudly announces compelling new test results highlighting the rapid and sustained antiviral power of Ion Gel ZCM-25®, a next-generation topical antimicrobial gel. These findings mark a significant advancement in the battle against viral infections, specifically the Dengue Virus Type 2 strain (ATCC VR-1584).
The efficacy study adhered to the Mexican Standard NMX-BB-040-SCFI-1999, a rigorous framework for germicidal product evaluation. Researchers applied a defined viral concentration to a 100-gram sample of Ion Gel ZCM-25® and measured reductions in viral load at two critical time points—10 minutes and 24 hours post-application.
Key Results:
These findings demonstrate the gel’s broad-spectrum and time-resistant efficacy, making it a promising candidate for clinical application in tropical and high-risk regions affected by dengue outbreaks.
The secret behind Ion Gel ZCM-25®’s efficacy lies in its innovative IBAL Technology (Ion Biotechnology Aqueous Ligands)—a patent-pending delivery system that enhances ion penetration at the cellular level. It contains a synergy of zinc (Zn²⁺), copper (Cu²⁺), magnesium (Mg²⁺), sulfur, and hydrogen, formulated in a redox-based hexaaqua ion matrix.
A preclinical study on systemic absorption, led by Dr. José Trinidad Pérez Urizar at the University of San Luis Potosí, confirmed high bioavailability. Topical application in animal models showed the active ions entered systemic circulation within 60 minutes—without accumulation—demonstrating efficient and safe transdermal delivery.
Over 36 scientific evaluations support Ion Gel ZCM-25®, each exploring its antimicrobial, antiviral, antifungal, and antibiofilm properties. These include laboratory challenges against high-priority pathogens like MRSA, Acinetobacter baumannii, and SARS-CoV-2.
You can review the growing library of antimicrobial studies that validate the gel’s multi-pathogen effectiveness and diverse mechanisms of action, ranging from membrane disruption to oxidative stress modulation and biofilm inhibition.
In a previous study conducted in 2020 at the Laboratory of Immunological Specialties, Ion Gel ZCM-25® was tested against SARS-CoV-2 (equine viral arteritis surrogate). The result? A stunning 99.9999% reduction in viral load within 10 minutes of contact. These consistent findings across viruses further support Ion Gel ZCM-25® as a potent virucidal solution in both pandemic and endemic scenarios.
Ion Gel ZCM-25® is not only an antiviral but also an effective tool for:
Healthcare providers have reported accelerated healing times, reduced inflammation, and prevention of secondary infections when using the product as an adjunctive therapy.
Ion Biotechnology is committed to advancing global health through safe, evidence-based biotechnological innovations. Ion Gel ZCM-25® is the result of over a decade of multidisciplinary research, developed under cGMP manufacturing standards, and supported by clinical and laboratory data.
For more details, scientific documentation, or purchasing options, visit the official website: https://zcm25.com/